• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Biocorp inks safety syringe deal with pharma player

November 29, 2017 By Brad Perriello

BiocorpBiocorp (PAR:ALCOR) said today that it inked a deal for its NewGuard safety syringe technology with “a leading global player specializing in pharmaceutical products” that it’s not allowed to name.

The Issoire, France-based company said the deal call for it to integrate and commercialize the NewGuard technology into the pharma partner’s pre-filled heparin syringes, saying the partner is the #2 player in the heparin space.

“This collaboration, which is expected to include more than 150 million NewGuard units, should earn Biocorp 10s of millions of euros in revenue by 2020-2022,” the company said.

Manufacturing is slated to begin after a nine-month evaluation phase to assess the deal’s sustainability and clarify its conditions, Biocorp said.

“We are delighted and honored to have signed this partnership. This first strategic collaboration with a global pharmaceutical giant is a true recognition of our know-how and expertise in improving the delivery of drugs. This is a new strategic step for Biocorp, which is about to become, thanks to this agreement, a key global player in safety medical devices,” COO Eric Dessertenne said in prepared remarks.

NewGuard is a passive safety device that uses a rigid needle shield and is designed to be compatible with a variety of filling, sterilization and packaging processes, Biocorp said.

ALCOR shares closed up 1.9% at €10.70 (about $12.69) apiece today in Paris.

($1 = €0.842946)

Filed Under: Drug-Device Combinations, Featured Tagged With: biocorp

IN CASE YOU MISSED IT

  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS